Mirtazapine Effects on REM Sleep
Yes, mirtazapine significantly increases REM latency (time to onset of REM sleep) and reduces REM sleep quantity. This is a well-documented effect of the medication that occurs through its antagonism of serotonin and histamine receptors.
REM Sleep Architecture Changes
Mirtazapine produces the following specific alterations to REM sleep parameters 1:
- Increased REM latency (delayed onset of first REM period)
- Decreased number of REM episodes throughout the night
- Increased duration of the first REM episode when it does occur
- Overall reduction in total REM sleep percentage
These effects were demonstrated in a polysomnographic study of 16 patients with major depressive disorder treated with mirtazapine 30 mg, where the medication consistently altered REM sleep architecture while simultaneously improving other sleep parameters 1.
Additional Sleep Architecture Effects
Beyond REM suppression, mirtazapine produces beneficial changes in other sleep stages 1:
- Increased slow wave sleep (SWS), particularly in the first sleep cycle
- Reduced wake-after-sleep onset
- Improved subjective sleep quality on the Athens Insomnia Scale
A recent 2025 randomized controlled trial in older adults with chronic insomnia confirmed mirtazapine's efficacy, showing significant improvements in Insomnia Severity Index scores (-6.5 vs -2.9 for placebo, p=0.003) 2.
Mechanism and Clinical Context
The REM-suppressing effects of mirtazapine are consistent with most antidepressants that enhance serotonin function 3. However, mirtazapine's unique mechanism as an alpha-2 adrenergic receptor antagonist also contributes to its sleep-promoting properties. One study demonstrated that mirtazapine normalized the blunted REM sleep response to clonidine in depressed patients, suggesting effects on alpha-2 adrenergic receptor sensitivity 4.
Important Caveats
While mirtazapine effectively suppresses REM sleep, this is not necessarily harmful. The FDA labeling notes "abnormal dreams" as an adverse effect occurring in 4% of patients (vs 1% placebo) 5, but the REM suppression itself may contribute to the medication's antidepressant and sleep-promoting effects. The clinical trials showed that despite REM suppression, patients experienced overall improved sleep quality and reduced depressive symptoms 1.
The most common adverse effects limiting use are somnolence (54% vs 18% placebo) and weight gain (12% vs 2% placebo) 5, not REM-related phenomena.